Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Diclofenac + Capsaicin Gel vs Diclofenac Gels
NCT03074162Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of diclofenac and capsaicin 8% patch in acute lumbago and osteoarthritis (OA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Plasma Concentration-time Curve Over One Dosing Interval at Steady State at Day 7 and Maximum Plasma Concentration at Steady State at Day 7. Started Apr 2017; status: completed.
02
Drugs
diclofenaccapsaicin 8% patch
03
Conditions
acute lumbagoosteoarthritis (OA)
Beyond the preview
Go deeper on NCT03074162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074162.